Re-treatment with interferon alfa of patients with chronic hepatitis C

被引:33
作者
Chow, WC
Boyer, N
Pouteau, M
Castelnau, C
Martinot-Peignoux, M
Martins-Amado, V
Degos, F
Maghinici, C
Sinegre, M
Benhamou, JP
Degott, C
Erlinger, S
Marcellin, P [1 ]
机构
[1] Hop Beaujon, Serv Hepatol, INSERM, U481, F-92118 Clichy, France
[2] Hop Beaujon, Ctr Claude Bernard Rech Hepatites Virales, Clichy, France
[3] Hop Beaujon, Serv Pharm, Clichy, France
[4] Hop Beaujon, Serv Anat & Cytol Pathol, Clichy, France
关键词
D O I
10.1002/hep.510270432
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Treatment of patients with chronic hepatitis C has had limited success because of relapses and nonresponse to interferon alfa therapy (currently the only established therapeutic agent), A retrospective study was done to determine the efficacy of re-treatment with interferon and the predictors of response in patients who failed to achieve sustained response after one standard course of interferon therapy (3 million units three times a week for 24 weeks), One hundred and eleven patients (47 relapsers and 64 nonresponders), mean age 45 years, were included in the study Eighteen relapsers and 13 nonresponders received a higher dose (5 MU), and 11 relapsers and 6 nonresponders received a longer duration (48 weeks) of interferon therapy The remaining patients received the same regimen as the first treatment, Eighty-one percent and 23% of relapsers and nonresponders, respectively, had an end-of-treatment response, and 19% and 3% of the corresponding patient groups had a sustained response to re-treatment. Two patients with breakthrough during their first treatment were the only nonresponders with sustained response after re-treatment. Sustained response was observed only in patients who received an increased dose or duration of interferon therapy No predictor of sustained response was found, In conclusion, sustained response to re-treatment with interferon was only observed with augmentation of dose or duration of therapy in some relapsers and patients who had breakthrough. Established predictors of response to interferon in naive patients, in particular serum hepatitis C virus RNA and genotype, were not associated with sustained response to re-treatment.
引用
收藏
页码:1144 / 1148
页数:5
相关论文
共 27 条
  • [21] MIELLA M, 1995, GASTROENTEROLOGY, V42, P201
  • [22] Side effects of high-dose interferon therapy for chronic hepatitis C
    Okanoue, T
    Sakamoto, S
    Itoh, Y
    Minami, M
    Yasui, K
    Sakamoto, M
    Nishioji, K
    Katagishi, T
    Nakagawa, Y
    Tada, H
    Sawa, Y
    Mizuno, M
    Kagawa, K
    Kashima, K
    [J]. JOURNAL OF HEPATOLOGY, 1996, 25 (03) : 283 - 291
  • [23] Payen J. L., 1996, Hepatology, V24, p273A
  • [24] SARACCO G, 1993, HEPATOLOGY, V18, P1300, DOI 10.1002/hep.1840180603
  • [25] COMBINED TREATMENT WITH INTERFERON-ALPHA-2B AND RIBAVIRIN FOR CHRONIC HEPATITIS-C IN PATIENTS WITH A PREVIOUS NONRESPONSE OR NONSUSTAINED RESPONSE TO INTERFERON ALONE
    SCHVARCZ, R
    YUN, ZB
    SONNERBORG, A
    WEILAND, O
    [J]. JOURNAL OF MEDICAL VIROLOGY, 1995, 46 (01) : 43 - 47
  • [26] TOYODA H, 1994, AM J GASTROENTEROL, V89, P1453
  • [27] VANTHIEL DH, 1994, GASTROENTEROLOGY, V106, pA1002